




Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Healthy Meningococcal-Naïve Children Aged 2–9 Years: A Phase III, Randomized Study

Participants achieving the hSBA seroresponse* at Day 30 by serogroup



Conclusion:

MenACYW-TT was well-tolerated in children, and achieved non-inferior immune responses to MenACWY-CRM against each of the vaccine serogroups.

*hSBA titers $\geq 1:16$ at Day 30 for a participant with Day 0 titers of $< 1:8$, or at least a 4-fold increase if Day 0 titers were $\geq 1:8$.

hSBA, serum bactericidal antibody assay with human complement.